[1] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[2] Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

[3] Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

[4] Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

[5] Vedolizumab as induction and maintenance therapy for ulcerative colitis

[6] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

[7] Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab

[8] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

[9] Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

[10] Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications

[11] Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice

[12] Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

[13] Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

[14] Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial

[15] Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial